Top

Published in:

Open Access 01-12-2023 | Review

Tumor immune microenvironment (TIME) to enhance antitumor immunity

Authors: Sajin Rajbhandary, Hari Dhakal, Sudip Shrestha

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

The tumor microenvironment is a result of dynamic interaction between different cellular and non-cellular components. In its essence it is not a solo performer, but an ensemble of performers that includes cancer cells, fibroblasts, myo-fibroblasts, endothelial cells and immune cells. The short review highlights important immune infiltrates within the tumor microenvironment that shape cytotoxic t lymphocyte (CTL)-rich immune hot and CTL-deficient immune cold tumors and novel strategies that have potential role in enhancing our immune responses in both immune hot and immune cold tumors.

Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46.CrossRefPubMed

Baghban R, Roshangar L, Jahanban-Esfahlan R, et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18:59. https://doi.org/10.1186/s12964-020-0530-4.CrossRefPubMedPubMedCentral

McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154–8.PubMedPubMedCentral

Lurquin C, Van Pel A, Mariamé B, De Plaen E, Szikora JP, Janssens C, Reddehase MJ, Lejeune J, Boon T. Structure of the gene of tum-transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell. 1989;58(2):293–303. https://doi.org/10.1016/0092-8674(89)90844-1.CrossRefPubMed

Foley EJ. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 1953;13(12):835–7.PubMed

Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–45. https://doi.org/10.1038/nm.3909. (Epub 2015 July 20).CrossRefPubMedPubMedCentral

Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–50. https://doi.org/10.1038/s41591-018-0014-x. (Epub 2018 Apr 23).CrossRefPubMedPubMedCentral

Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44–9. https://doi.org/10.1126/science.1198687.CrossRefPubMedPubMedCentral

Cachot A, Bilous M, Liu YC, et al. Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Sci Adv. 2021;7(9): eabe3348. https://doi.org/10.1126/sciadv.abe3348.CrossRefPubMedPubMedCentral

10.

Reissfelder C, Stamova S, Gossmann C, et al. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis [published correction appears in J Clin Invest. 2015;125(3):1364]. J Clin Invest. 2015;125(2):739–51. https://doi.org/10.1172/JCI74894.CrossRefPubMed

11.

Tian C, Lu S, Fan Q, et al. Prognostic significance of tumor-infiltrating CD8⁺ or CD3⁺ T lymphocytes and interleukin-2 expression in radically resected non-small cell lung cancer. Chin Med J. 2015;128(1):105–10. https://doi.org/10.4103/0366-6999.147828.CrossRefPubMedPubMedCentral

12.

Yuan Y, Zhu Z, Lan Y, et al. Development and validation of a CD8+ T cell infiltration-related signature for melanoma patients. Front Immunol. 2021;12: 659444. https://doi.org/10.3389/fimmu.2021.659444.CrossRefPubMedPubMedCentral

13.

Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135–46. https://doi.org/10.1038/nrc3670.CrossRefPubMed

14.

Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol. 2021;12: 636568. https://doi.org/10.3389/fimmu.2021.636568.CrossRefPubMedPubMedCentral

15.

Zarychta E, Ruszkowska-Ciastek B. Cooperation between angiogenesis, vasculogenesis, chemotaxis, and coagulation in breast cancer metastases development: pathophysiological point of view. Biomedicines. 2022;10(2):300. https://doi.org/10.3390/biomedicines10020300.CrossRefPubMedPubMedCentral

16.

Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep. 2015;13(2):412–24. https://doi.org/10.1016/j.celrep.2015.08.077. (Epub 2015 Sep 24).CrossRefPubMedPubMedCentral

17.

Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399–416. https://doi.org/10.1038/nrclinonc.2016.217. (Epub 2017 Jan 24).CrossRefPubMedPubMedCentral

18.

Dysthe M, Parihar R. Myeloid-derived suppressor cells in the tumor microenvironment. Adv Exp Med Biol. 2020;1224:117–40. https://doi.org/10.1007/978-3-030-35723-8_8.CrossRefPubMed

19.

van Dalen FJ, van Stevendaal MHME, Fennemann FL, et al. Molecular repolarisation of tumour-associated macrophages. Molecules. 2018;24(1):9. https://doi.org/10.3390/molecules24010009.CrossRefPubMedPubMedCentral

20.

Mok TSK, Wu YL, Kudaba I, KEYNOTE-042 Investigators, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30. https://doi.org/10.1016/S0140-6736(18)32409-7. (Epub 2019 Apr 4).CrossRefPubMed

21.

Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46. https://doi.org/10.1056/NEJMoa1910836. (Epub 2019 Sep 28).CrossRefPubMed

22.

O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16:151–67.CrossRefPubMed

23.

Tutt AL, O’Brien L, Hussain A, et al. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol. 2002;168(6):2720–8. https://doi.org/10.4049/jimmunol.168.6.2720.CrossRefPubMed

24.

vanKooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67(1):2–17. https://doi.org/10.1002/jlb.67.1.2.CrossRef

25.

Weiss S, Sznol M, Shaheen M, et al. 389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy. J ImmunoTherapy Cancer. 2021. https://doi.org/10.1136/jitc-2021-SITC2021.389.CrossRef

26.

American Association for Cancer Research. A CD40 agonistic antibody shows signs of efficacy in pancreatic cancer. Cancer Discov. 2021;11(3):OF7. https://doi.org/10.1158/2159-8290.CD-RW2021-006.CrossRef

27.

Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17–35. https://doi.org/10.1016/j.immuni.2019.12.011.CrossRefPubMed

28.

Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.CrossRefPubMed

29.

Geuijen C, Tacken P, Wang LC, Klooster R, et al. A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade. Nat Commun. 2021;12(1):4445. https://doi.org/10.1038/s41467-021-24767-5.CrossRefPubMedPubMedCentral

30.

Cannarile MA, Weisser M, Jacob W, et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5(1):53. https://doi.org/10.1186/s40425-017-0257-y.CrossRefPubMedPubMedCentral

31.

Song JS, Chang CC, Wu CH, et al. A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment. Proc Natl Acad Sci USA. 2021;118(13): e2015433118. https://doi.org/10.1073/pnas.2015433118.CrossRefPubMedPubMedCentral

32.

Feng Y, Mu R, Wang Z, et al. A toll-like receptor agonist mimicking microbial signal to generate tumor-suppressive macrophages. Nat Commun. 2019;10(1):2272. https://doi.org/10.1038/s41467-019-10354-2.CrossRefPubMedPubMedCentral

33.

Schürch CM, Roelli MA, Forster S, et al. Targeting CD47 in anaplastic thyroid carcinoma enhances tumor phagocytosis by macrophages and is a promising therapeutic strategy. Thyroid. 2019;29(7):979–92. https://doi.org/10.1089/thy.2018.0555. (Epub 2019 May 10).CrossRefPubMedPubMedCentral

34.

Felip E, Brunsvig P, Vinolas N, et al. A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy. J Clin Oncol. 2019;37(15_suppl):9098–9098.CrossRef

Title: Tumor immune microenvironment (TIME) to enhance antitumor immunity
Authors: Sajin Rajbhandary
Hari Dhakal
Sudip Shrestha
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01125-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tumor immune microenvironment (TIME) to enhance antitumor immunity

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Research on the effectiveness and safety of bronchial thermoplasty in patients with chronic obstructive pulmonary disease

EBUS-GS with the GeneXpert MTB/RIF assay for diagnosis of Mycobacterium tuberculosis infection of isolated pulmonary nodules

Predictors of neurologic outcomes and mortality in physically abused and unintentionally injured children: a retrospective observation study

A study on endovascular treatment alone and bridging treatment for acute ischemic stroke

Are bacterial coinfections really rare in COVID-19 intensive care units?

The risk factors of the 72-h unscheduled return visit admission to emergency department in adults below 50 years old